A genomic signature for accurate classification and prediction of clinical outcomes in cancer patients treated with immune checkpoint blockade immunotherapy

Tumor mutational burden (TMB) is associated with clinical response to immunotherapy, but application has been limited to a subset of cancer patients. We hypothesized that advanced machine-learning and proper modeling could identify mutations that classify patients most likely to derive clinical bene...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Mei, Wu, Kuan-Han Hank, Trudeau, Sheri, Jiang, Margaret, Zhao, Joe, Fan, Elliott
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7688643/
https://www.ncbi.nlm.nih.gov/pubmed/33239757
http://dx.doi.org/10.1038/s41598-020-77653-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7688643/
https://www.ncbi.nlm.nih.gov/pubmed/33239757
http://dx.doi.org/10.1038/s41598-020-77653-3

Ejemplares similares